Nuclear factor kappa B ligand (RANKL) was associated with the activation of NF-kB, which could lead to bone erosion and bone destruction, and the use of RANKL inhibitors could inhibit bone loss in RA by interfering with osteoclasts (28). This evidence concerns the gene TNFSF11 and rheumatoid arthritis.